A subsequent German clinical trial on patients with melanoma demonstrated that BRAF/MEK inhibitors could induce much superior therapeutic responses in patients harboring a coexisting BRAF mutation and TERT promoter mutation compared with patients harboring only a BRAF mutation (25). This evidence concerns the gene BRAF and melanoma.